OncoMatch/Clinical Trials/NCT05547529
The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer
Is NCT05547529 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for esophageal cancer.
The purpose of this study is to evaluate the safety, feasibility and outcomes of neoadjuvant chemotherapy followed by esophagectomy versus neoadjuvant chemoradiotherapy followed by esophagectomy for locally advanced resectable esophageal squamous cell carcinoma cT3-4aN0M0, cT1-4aN1-3M0. This is non-inferiority study (neoadjuvant chemoradiotherapy has no advantage over neoadjuvant chemotherapy).
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1-4AN1-3M0 (AJCC/UICC 8th Edition)
Excluded: Stage CT4BCN0CM0
Clinical stage cT1-4aN1-3M0 (AJCC/UICC 8th Edition). Clinical stage cT4bcN0cM0 (AJCC/UICC 8th Edition) [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiotherapy
Cannot have received: targeted therapy
Lab requirements
Blood counts
white blood cells > 3.0 x 109/l; neutrophil > 2.0 × 109/l; hemoglobin > 90 g/l; platelets > 100 x 109/l
Kidney function
glomerular filtration rate (ccr) > 50 ml/min
Liver function
total bilirubin < 1.5 x uln; ast and alt < 3.0 x uln
Cardiac function
left ventricular ejection fraction > 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify